Drugs that contain Morphine Sulfate

1. List of Arymo Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549899 ZYLA Abuse deterrent pharmaceutical compositions for controlled release
Jul, 2033

(10 years from now)

US9044402 ZYLA Abuse-deterrent pharmaceutical compositions for controlled release
Jul, 2033

(10 years from now)

Market Authorisation Date: 09 January, 2017

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of ARYMO ER before it's patent expiration?
More Information on Dosage

2. List of Morphabond Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10314788 DAIICHI SANKYO INC Pharmaceutical compositions configured to deter dosage form splitting
Aug, 2028

(5 years from now)

US7955619 DAIICHI SANKYO INC Abuse resistant drugs, method of use and method of making
Aug, 2028

(5 years from now)

Market Authorisation Date: 02 October, 2015

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of MORPHABOND ER before it's patent expiration?
More Information on Dosage

3. List of Morphine Sulfate drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248229 FRESENIUS KABI USA Packaging system for oxygen-sensitive drugs
Mar, 2034

(11 years from now)

US9072781 FRESENIUS KABI USA Morphine formulations
Mar, 2034

(11 years from now)

US9192608 FRESENIUS KABI USA Morphine formulations
Mar, 2034

(11 years from now)

Market Authorisation Date: 30 October, 2013

Treatment: Management of chronic pain in patients requiring opioid analgesia; Treatment of pain

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic